Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 06 04 2018
entrez: 28 7 2019
pubmed: 28 7 2019
medline: 7 1 2020
Statut: epublish

Résumé

Background: Precise staging of esophageal cancer (EC) is important for selection of optimal treatment option and prognostication. Aim of this study was to assess the role of 18FDG PET/CT in staging and response evaluation to neoadjuvant chemoradiation (nCR) in EC patients using standardized imaging protocol. Material and methods: This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan University Hospital Karachi, Pakistan from July 2017 till February 2018. We included 34 biopsy proven EC patients who had 18FDG PET/CT and CT of neck, chest and abdomen as part of initial staging. Eleven patients had post-nCR 18FDG PET/CT using standardized imaging protocol as per EANM guidelines. CT and PET/CT based staging was compared. Based on PERCIST criteria, response evaluation was assessed using change in highest SUVmax (%ΔSUVmax) in baseline and follow-up scans (primary lesion, node or extra-nodal metastases). Results: Mean age of cohort was 57 ± 14 years (23 males and 11 females) having adenocarcinoma (AC) in 23 and squamous cell cancer (SCC) in 11 patients. Mean 18FDG dose, uptake time and hepatic SUVmean for baseline scans were 169 ±54 MBq, 65 ±10 minute and 1.91 ± 0.49 which were within ± 10%, ± 15% and ± 20% for follow-up scans in 11 patients respectively. Mean size (craniocaudal dimension in mm) and SUVmax of primary tumor was 56 ±27 mm and 13.4 ± 4.7. Based on 18FDG PET/CT findings, patients were categorized into N0 (10/34), N1 (09/34), N2 (11/34) and N3 (04/34) while 11/32 had stage IV disease. No significant difference was seen in AC and SCC groups. CT found stage IV disease in 3/34 (09%) while PET/CT found in 11/34 (32%; p value: 0.019) cases. PET/CT showed concordance with CT in 41% while discordance (all with upstaging) seen in 59%. On follow-up PET/CT, complete metabolic response was seen in 5/11 (45%) and partial metabolic response was noted in 6/11 (55% - p value non-significant) patients. Median %ΔSUVmax over primary lesions was 49.84% (-32.69 -100%) while over nodal sites it was 41.18% (-82.60 -100%). Conclusion: We conclude that 18FDG PET/CT was found a sensitive tool in initial staging of EC. Compared with CT, it had higher diagnostic accuracy for distant nodal and extra-nodal metastasis. %ΔSUVmax between baseline and post-nCR studies acquired with standardized protocol had changed management in more than half of our patients. For response evaluation in EC more studies with standardized 18FDG PET/CT imaging protocols are warranted.

Identifiants

pubmed: 31350957
doi: 10.31557/APJCP.2019.20.7.2003
pmc: PMC6745203
pii:
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2003-2008

Références

J Nucl Med. 2012 Jun;53(6):864-71
pubmed: 22582047
J Nucl Med. 2017 May;58(5):723-729
pubmed: 27738011
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3357-3363
pubmed: 29286604
Crit Rev Oncol Hematol. 2016 Nov;107:128-137
pubmed: 27823640
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61
pubmed: 18931839
Ann Surg Oncol. 2012 Jul;19(7):2142-8
pubmed: 22395974
Dtsch Arztebl Int. 2015 Aug 17;112(33-34):545-52
pubmed: 26356551
Asian Pac J Cancer Prev. 2014;15(18):7719-24
pubmed: 25292052
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2011 Dec;52 Suppl 2:93S-100S
pubmed: 22144561
Sci Rep. 2015 Aug 05;5:11075
pubmed: 26242464
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Eur J Cancer. 2015 Nov;51(17):2545-52
pubmed: 26321501
World J Gastrointest Oncol. 2014 May 15;6(5):112-20
pubmed: 24834141
Asia Ocean J Nucl Med Biol. 2016 Summer;4(2):59-65
pubmed: 27408893
Arq Gastroenterol. 2016 Jan-Mar;53(1):44-8
pubmed: 27281504
Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):759-69
pubmed: 16470369
Radiographics. 2014 Oct;34(6):1722-40
pubmed: 25310426
Clin Endosc. 2014 Nov;47(6):523-9
pubmed: 25505718
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219

Auteurs

Nosheen Fatima (N)

Section of NM and PET/CT Imaging, Department of Radiology, Aga Khan University Hospital (AKUH), Karachi, Pakistan. Email: maseeh.uzzaman@aku.edu

Maseeh Uz Zaman (MU)

Section of NM and PET/CT Imaging, Department of Radiology, Aga Khan University Hospital (AKUH), Karachi, Pakistan. Email: maseeh.uzzaman@aku.edu

Areeba Zaman (A)

Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan.

Unaiza Zaman (U)

Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan.

Rabia Tahseen (R)

Department of Radiation Oncology, Aga Khan University Hospital (AKUH), Karachi, Pakistan.

Sidra Zaman (S)

Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH